ResMed Acquires HB Healthcare to Help Millions of Koreans Living with Sleep Apnea, Other Respiratory Conditions
ResMed (NYSE: RMD, ASX: RMD), a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, today announced that is has completed the acquisition of HB Healthcare (HBH) to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions.
HBH, a fast-growing privately owned South Korean home medical equipment provider, serves both reimbursed and cash-pay customers of sleep and respiratory care devices. ResMed intends to reach millions more patients through HBH and its wider network of trusted distributor partners.
“ResMed has reaffirmed its leading role in Korea’s CPAP and respiratory care market, and commitment to improving millions of Koreans’ breathing and quality of life,” said Kim Ho Kyun, ResMed Korea’s Sales and Marketing director. “With HBH and our valued distribution partners in Korea, ResMed can maximize the number of people who can enjoy the benefits of life-changing cloud-connected sleep and respiratory therapy.”
Sleep apnea in Korea
One in five Korean adults is believed to have sleep apnea, according to a study by Ansan Hospital, Korea University and the Korea Center for Disease Control and Prevention. ResMed believes that the Korean population is highly underserved, and that increased awareness among Koreans and their doctors can lead to better diagnosis rates, treatment and overall health outcomes.
The Korean government’s July 2018 decision to commence National Health Insurance Service reimbursement for sleep apnea diagnosis and CPAP treatment devices, such as ResMed's AirSense 10 and AirMini (the world’s smallest CPAP), can help encourage people with sleep apnea to seek the in-home treatment they need.
Respiratory care in Korea
Koreans required to use home ventilation to help treat their COPD or other lung disease may be eligible to rent from ResMed’s comprehensive range of ventilators through their health insurance provider.
Plus, a 2018 study showed that combining a home ventilator with home oxygen therapy significantly reduced COPD-related hospital readmissions and – in a rare finding – saved people money over the long term.
ResMed provides a comprehensive range of home ventilators through its distribution partners to patients as well. Those ventilators will be cloud-connectable later this year.
“We’re excited to join the ResMed family and, together, help provide life-changing, cloud-connectable devices to millions of Koreans living with sleep apnea, COPD and other chronic diseases,” said Hong Seung Chul, HB Healthcare’s director of patient management.
ResMed has sold sleep and respiratory care devices in Korea for more than a decade, and has consistently led efforts in the delivery of quality healthcare services to Korean customers with consistent, innovative services and support for official partners across the country.
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Concierge Auctions and Engel & Völkers to Sell $29.9 Million New Jersey Estate Without Reserve20.5.2019 17:32:00 CEST | Pressemelding
A 32,507-square-foot Saddle River residence will sell at auction next month via leading global firm Concierge Auctions. Known as “Stone Palace on the Hill,” the home features a glass elevator, tennis court, racquetball court, wine cellar, and two swimming pools. 144 East Saddle River Road was previously listed for $29.9 million and will sell Without Reserve in cooperation with Alina Pogorelova and Lisa Troyano-Ascolese of Engel & Völkers. Bidding, which will be held via Concierge Auctions’ online marketplace, will open on June 21st and close on June 27. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005686/en/ 144 East Saddle River Road | New York Metro, NJ (Photo: Business Wire) “The quality of work and detail that went into building this home is perhaps the most impressive element of the property,” said Troyano-Ascolese. “With astounding details from custom gold-plated and forged-iron railings to a complete hand-cut
CNIM to Optimize Renewable Heat Production for Nantes District Heating20.5.2019 17:20:00 CEST | Pressemelding
CNIM, a French international industrial equipment manufacturer and integrator, has entered into an agreement concerning the energy efficiency optimisation at the waste-to-energy plant serving the cities of Nantes and Saint Nazaire, in the North West of France. Under the terms of this agreement, CNIM will install an absorption heat pump to boost the supply of hot water to Nantes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005678/en/ Heat-Pump_13MW_Brive (c) CNIM The delivery is scheduled for October 2019. The new system has been designed to inject 3.1 MW of heat energy into Nantes' district heating system. 2018: Two contracts to upgrade heat networks in France and Switzerland Prior to this agreement, CNIM won two other major contracts to upgrade the energy efficiency of waste-to-energy plants in France and Switzerland, and to supply district heating networks with renewable energy. Supplying 30 MW to Basel's district
MyHeritage utvides til Helse; Lanserer ny DNA-test som tilbyr omfattende og personlig helseinnsikt for forbrukere20.5.2019 17:15:00 CEST | Pressemelding
MyHeritage, den ledende globale tjenesten for familiehistorie og DNA-testing, kunngjorde i dag en stor utvidelse av DNA-produktlinjen med lanseringen av MyHeritage DNA Helse+Aner-testen. Testen gir en ny dimensjon av genetisk innsikt med omfattende helserapporter som kan styrke fremtidige helse- og livsstilsvalg. Det er en utvidelse av den nåværende MyHeritage DNA-testen, og inkluderer sine søylefunksjoner: en prosentvis nedbryting av etnisk opprinnelse og samsvar med slektninger gjennom delt DNA. MyHeritage er nå det eneste globale DNA-selskapet for forbrukere som tilbyr et omfattende helse- og aneprodukt på over 40 språk. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20190520005670/no/ MyHeritage utvides til Helse; Lanserer ny DNA-test som tilbyr omfattende og personlig helseinnsikt for forbrukere (Graphic: Business Wire) Lanseringen av Helse+Aner-produktet skiller MyHeritage som den eneste hovedtjenesten som forbinde
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD120.5.2019 16:46:00 CEST | Pressemelding
Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results show that nintedanib slows the loss of pulmonary function in patients with SSc-ILD compared to placebo. Patients taking nintedanib showed a 44% reduction in the rate of decline of their lung function, measured in FVC assessed over 52 weeks1. These new data were today published in the New England Journal of Medicine (NEJM) and presented to the medical community at the American Thoracic Society (ATS) International Conference, in Dallas, USA. SENSCIS® is the largest randomised controlled trial to be conducted in patients with SSc-ILD, a disease for which there are currently no approved treatments.1,3,4 Results also showed that nintedanib had a safety and tolerability profile similar to that observed in patients with idiopathic pulmonary fibro
Airship Bolsters its Senior Leadership Team for Accelerated Global Growth20.5.2019 13:00:00 CEST | Pressemelding
Customer engagement company Airship today announced four senior leadership appointments including Dale Flores as vice president of sales Americas, Neil Gariepy as vice president of infrastructure and security, David King Harris as vice president of sales EMEA, and Jeff Winsor as vice president of technology services. Dale Flores will lead the rapid expansion of Airship’s Americas sales organization, growing solution adoption to generate greater business value for customers throughout the region. Flores brings two decades of global SaaS sales and customer success management experience to Airship, including over 14 years leading sales teams at Silverpop and IBM. Most recently, Flores was head of customer success at digital customer experience company Clicktale. Neil Gariepy will lead Airship’s customer engineering, infrastructure and security teams, with responsibility for expanding Airship’s infrastructure globally while further optimizing its cost, performance and security. Gariepy bri
Analogix Introduces Its VirtualLink™ Reference Design for High-Performance Gaming Notebooks20.5.2019 13:00:00 CEST | Pressemelding
Analogix Semiconductor, Inc. today announced the availability of its VirtualLink™ Reference Design which enables VirtualLink directly on the motherboard of high-performance gaming notebooks, allowing them to support virtual reality (VR) over the USB-C™ connector. External accessories can also leverage the reference design to interface legacy graphics processing units (GPUs) to future VirtualLink-enabled VR head-mounted displays. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005132/en/ Analogix VirtualLink™ Reference Design brings VR support over the USB-C™ connector to high-performance gaming laptops. (Graphic: Business Wire) Introduced by a consortium led by NVIDIA, Oculus, Valve, AMD, and Microsoft, the VirtualLink Alternate Mode of USB Type-C™ was designed to deliver the power, display, and data required to power VR headsets through a single USB Type-C connector, eliminating the need for multiple cables. It expands